The main purpose of this legislation is to enhance oversight of foreign investment in the U.S. pharmaceutical industry. It aims to ensure that such investments do not negatively impact the domestic production of drugs and related technologies, thereby safeguarding public health and national security. Key provisions of the legislation require the Federal Trade Commission (FTC) to produce a report on foreign investments in the pharmaceutical sector. This report must be submitted within one year of the law's enactment and annually thereafter.